LLY v. NVO: Weighing Who's Winning the GLP-1 Industry

Core Viewpoint - The GLP-1 market is highly competitive, with Novo Nordisk and Eli Lilly as key players, each offering different products and pricing strategies to capture market share. Group 1: Product Offerings and Pricing - Novo Nordisk has launched a higher dose version of Wegovy in the US, priced at $399 for cash customers and about $25 for those with insurance, undercutting Eli Lilly's Zepbound by approximately $100 [1] - Eli Lilly's Zepbound and Mounjaro are viewed as market leaders due to their efficacy, with tirzepatide (Zepbound) being considered the most effective product currently available [4][5] - Novo Nordisk has also introduced a pill version of its product, expected to be available in 2026, expanding its range of injectables [2] Group 2: Market Dynamics and Competition - Efficacy is the primary driver of market share, with Zepbound currently holding a superior position unless a product demonstrates significantly increased effectiveness [5][6] - Eli Lilly is seen as having a strong pipeline of future products, including retatrutide, which may offer higher weight loss percentages and cater to more extreme cases [7][8] - As competition increases, prices are expected to decline, leading to higher demand, particularly among cash-paying consumers who are more price-sensitive [10][12] Group 3: Company Outlooks - Eli Lilly is on a positive outlook due to its growth story, investments in manufacturing and R&D, and improving balance sheet [14][15] - Novo Nordisk is currently rated with a stable outlook, having started with lower leverage compared to Eli Lilly [16] - The injectables are expected to remain the primary treatment method, despite the introduction of pill forms, as they are more effective and have established usage among diabetes patients [18][19] Group 4: Future Developments - Other pharmaceutical companies, such as Amgen and Pfizer, are entering the GLP-1 market with products that may require less frequent dosing, although none currently appear to surpass Zepbound in effectiveness [21][22][23]